The synthesis and biological properties of the new penem antibiotic MEN10700 (6) and of its selected oral prodrug MEN11505 (8f) are described. MEN10700 showed a broad spectrum of activity, with high potency both on Gram-positive and Gram-negative strains. It also exhibited good antibacterial activity toward anaerobes and on strains selected for their resistance to other antibacterial agents (cefotaxime-or ceftazidime-resistant Gram-negative strains, ciprofloxacin-resistant E. coli, extended spectrum /3-lactamase producing and cephalosporinase inducible enterobacteria). MEN 10700 showed a very high stability to enzymatic degradation by renal dehydropeptidase DHP-I. After oral administration in rats of the pivaloyloxymethyl ester prodrug MEN1 1505, the relative bioavailability of MEN10700 was calculated as F=43%.
The development of bacterial resistance to existing antibiotics is a phenomenon of concern to the clinician, being a major cause of failure in the treatment of infectious diseases. Over the last years, increased resistance to established antibiotics has provided a continuous drive to the development of new antimicrobial agents. In addition, the emergence of opportunistic infections in immunocompromised individuals has created a need for effective therapy for unusual pathogens.
Due to their wide spectrum of activity, high potency and low toxicity, /3-lactam antibiotics still retain a prominent antibacterial spectrum includes anaerobic bacteria as well as Gram-positive and most Gram-negative pathogens: their small size and compact shape both contribute4^to the ability of penem compoundsto rapidly cross the outer membrane of Gram-negative bacteria. In addition, stability to /3-lactamases and to the renal dehydropeptidase DHP-I, and, most notably, the possibility of oral administration, provide considerable advantages of the penem series. Among the penems only one compound (faropenem) 5'6) is currently marketed for the oral therapy of respiratory tract, skin and soft tissue infections; other penems, e.g. ritipenem acoxil7 '8) and sulopenem,9) are in the advanced phases of Dedication: to the Memoryof Sir Edward Abraham. They all share a number of well established structural features, such as the presence of a free carboxy group at C-3 and 1-hydroxyethyl at C-6 and the (SR, 6S, 5R) configuration.
A large differentiation is allowed in the nature of C-2 group. With the aim of obtaining potent, broad spectrum antibacterial agents by improving the penetration through the outer membraneof Gram-negative bacteria, we carried out the synthesis of a series of penems bearing amino acid related side chains in position 2 as small, polar groups.10) Amongthem, the 2-sarcosinamidomethyl derivative 6 (MEN 10700) was selected for further development. In this paper we will describe the synthesis and biological properties of MEN 10700 and its selected oral prodrug MEN 1 1505 (8f).
Chemistry
The initial quantity of 6, necessary for screening tests, was prepared through the classical method11} for penems (Scheme 1), starting from the reaction of silyl protected 4-acetoxyazetidinone 1 with (2-fer^-butyldiphenylsilyloxy)-thioacetic acid to give 2a; following nitrogen acylation to obtain 3a and ring closure led to the bis-silyl protected penem 4a. Selective silyl deprotection, followed in sequence by mesylate formation on the primary alcoholic group and nucleophilic exchange with sarcosinamide,10) finally gave the fully protected 2-(sarcosinamido)methyl penem 4b. Usual deprotections steps allowed to obtain the desired compound 6 (MEN 10700). This method suffers however of a number of drawbacks that render it unsuitable for the preparation of multigram quantities ofpenem 6. The most critical step is the synthesis of4b from 4a. Insufficient selectivity is achieved both during silyl deprotection on the primary alcohol in position 2 and nucleophilic exchange on mesylate with sarcosinamide: this last reaction step suffers competition from /3-lactam ring opening by the same OCT. 2000 Scheme 2.
Reagents: (i): allyl oxalyl chloride, NEt3, toluene, 30' , 5°C; (ii): P(OEt)3, toluene, 1 10°C, 6 h Scheme 3.
reagent.10) In addition, the low stability of penem mesylate, together with the length of the whole synthetic pathway and the high cost of some reagents prompted us to look for shorter and more practicable methods. A more straighforward reaction pathway can be outlined, that removes the need for protecting groups in the sidechain by reacting directly the 4-acetoxy-azetidinone 1 with Af-thiocarboxymethyl-sarcosinamide to give 2b. Nitrogen acylation to 3b and penem ring closure should allow to obtain the protected penem 4b. Again, when we tested this synthetic route experimentally, selectivity appeared as the crucial problem, as acylation of 2b with allyl oxalyl chloride also occurred at the primary amide in the side chain (Scheme 2), giving a mixture of mono-and diacylated azetidinones 3b, 3d, 3e (see Experimental Section for details). Consequently, when the mixture was heated in toluene in the presence oftriethylphosphite in order to close the thiazoline ring, the cyanomethyl substituted penem 4d 
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Ritipenem lmg/ml Ritipenem 0.1 mg/ml MEN10700 control Ritipenemcontrol faropenem, with higher activity for MEN 10700 on Enterobacter and Citrobacter. Against anaerobes, MEN 10700 showed activity similar to that of imipenem, and was more potent than metronidazole, a "classical" anti-anaerobe agent, against all species except C. difficile and P anaerobius. In general MEN10700 was a much better anti-anaerobe agent than the cephalosporins and ciprofloxacin. MEN10700 showed a very high stability to enzymatic degradation by renal dehydropeptidase DHP-L The stability of MEN10700 to DHP-I was evaluated in comparison to the penem ritipenem, incubating both compoundsin the same solution to minimise differences. Results are outlined in Fig. 1 : after 190 minutes incubation at 37% and at a substrate concentration of 1 mg/ml, 68% of the initial amount of MEN10700 remained unchanged vs. 35% ofritipenem; at a substrate concentration of 0.1 mg/ml, residual amounts were 52% for MEN10700 and 13% for ritipenem after 205 minutes. Literature data22) for imipenem in comparable conditions gave only 5% of compound remaining after 3 hours (initial concentration: 1 mg/ml). (Table  1) : although the use of benzene as solvent gave the best selectivity (15 : 1 ratio of 3b vs. 3d+3e), the less toxic toluene was found preferable (85% total yield, 10 : 1 selectivity).
The crude 3b (containing about 9% of 3d+3e) coming from the previous step was dissolved in 14ml of toluene. -4.3, 18.0, 22.4, 25.7, 43.7, 55.1, 61.1, 61.9, 65.1, 65.7, 71.8, 118.6, 121.1, 131.5, 155.7, 159.5, 172.8, 172.9; MS(TS): m/z 470 (M+H)+) and the corresponding nitrile solution of 26.5 ml (0.190mol) of triethylamine in 50ml of dioxane was added dropwise over 1 hour. After stirring for stirred for 30 minutes, poured in a cold 3% NaHSO3 solution in water and extracted with ethyl acetate. The organic phase was washed with 3% NaHSO3, 5% NaHCO3, water, 10% NaCl and dried over anhydrous Na2SO4.
Evaporation of the solvent under vacuumgave an orangeyellow solid. Addition of pentane and filtration through a buchner funnel gave a pale yellow solid that was washed with pentane on the filter giving a white solid. Yield: 57 g -4.3, 17.9, 22.3, 25.7, 48.0, 52.4, 64.6, 65.4, 166.1, 194.8; MS (TS): mlz 338 (M+H)+, 355 (M+NH4)+. -4.3, 17.8, 21.7, 25.6, 47.9, 53.8, 64.7, 66.3, 67.4, 120.1, 130.5, 154.5, 159.0, 162.9, 190.7 To the toluene solution (250ml) containing crude 3c (0.055mol) was added triethylphosphite (20.7ml, 0.121mol) and the mixture refluxed for 3 hours. The solution is allowed to cool to room temperature, most of the solvent evaporated under vacuum and the residue, dissolved in 320ml of iV,A^-dimethylformamide, was used for the following step without any purification. Alternatively, 4c
could be isolated in 82% yield as a yellow oil.24)
To the solution of 4c in 320ml of N,Ndimethylformamide, obtained as described for the previous step, at roomtemperature, under nitrogen atmosphere, were added 16.9g (0.114mol) of sodium iodide. After 30 minutes, 9.78g (O.lll mol) of sarcosinamide were added and the mixture was stirred for about 2 hours. At the end of the reaction, the mixture was poured into iced 3% aq. NaHSO3 (200ml) and extracted three times with ethyl acetate. The organic phase was washed with 5% aq. NaHCO3 (3X70ml), with water and with brine. After drying over anhydrous Na2SO4,the solvent was evaporated under vacuum, giving an orange-red oil, that was crystallised by the aid of cold cyclohexane/ft-hexane 1 : 5 v/v, filtered and washed with hexane. Yield: 10.8 g (42% overall yield from 2b). White solid.
The synthesis of 6 from 4b through 5 has already been described.10) Compound 6 was obtained after freeze-drying as a white powder; mp: 133. Aliquots of0.5 ml ofa solution containing 2.00mg/ml of 6 and 2.00mg/ml of ritipenem in 0.025 m Tris-HCl buffer (pH=7) were added with 0.5ml of rat DHP-I and the samples incubated at 37°C for different times. Control: aliquots of 0.5ml of the same solution were added with 0.5 ml of water and stored at 37°C. For the parallel study at a substrate concentration of 0.1 mg/ml, 1 ml of the solution containing 6 and ritipenem was diluted to 10ml with 0.025m Tris-HCl buffer (pH=7). 
